University of Kentucky Deparment of Neurosurgery, UK Chandler Hospital
Lexington, Kentucky, 40536-0298, United States
NCT Number: NCT02514902
In the search for a novel marker of stroke that could be rapidly assessed in blood, the investigators developed a point-of-care (POC) lateral flow device (LFD) that rapidly (< 15 min) detects levels of a biomarker that is released into blood following neuronal injury associated with stroke and traumatic brain injury. The protein's expression in human brain should serve as a useful biomarker of neuronal injury in stroke and traumatic brain injury.
Looking for future studies?
Notify Me21 year–85 year
All sexes
Interventional
Not applicable
Lexington, Kentucky, 40536-0298, United States
The use of a lateral flow device (LFD) to indicate the presence of a blood biomarker is feasible and may provide an important diagnostic tool for stroke and traumatic brain injury (TBI).
Primary Objectives:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A drop of whole blood from a finger stick is placed on the lateral flow device at two different time points to indicate the presence of a neuronal specific biomarker. The results will also be correlated to severity of clinical and radiographic injury. Separate drops are evaluated similarly for serum levels. The objective is to determine feasibility of a diagnostic tool for stroke (ischemic and hemorrhagic and traumatic brain injury (TBI). No diagnostic results or resulting treatments will be applied to any subject.
Time frame: Within 8 hours of time of injury/onset of stroke symptoms.
Degree of response to a protein specific biomarker in whole blood as indicated by the Lateral Flow Device's analog scale: negative / mild / moderate / severe.
Time frame: Within 48 ± 8 hours of time of injury/onset of stroke symptoms.
Degree of response to a protein specific biomarker in whole blood as indicated by the Lateral Flow Device's analog scale: negative / mild / moderate / severe.
Time frame: Within 8 hours of time of injury/onset of stroke symptoms.
Degree of response to a protein specific biomarker in serum as indicated by the Lateral Flow Device's analog scale: negative / mild / moderate / severe.
Time frame: Within 48 ± 8 hours of time of injury/onset of stroke symptoms.
Degree of response to a protein specific biomarker in serum as indicated by the Lateral Flow Device's analog scale: negative / mild / moderate / severe.
Justin Fraser
Other
Acronym: STABILISER-I
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04496076
Brain Diseases, Brain Injuries
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06134921
Brain Diseases, Cardiovascular Diseases
Salaya, Nakonpathom, Thailand
View Trial DetailsNCT04279067
Brain Diseases, Cardiovascular Diseases
Irvine, California, United States
View Trial DetailsNCT07200661
Brain Diseases, Cardiovascular Diseases
Chiang Rai, Chiangrai, Thailand
View Trial Details